It has been discovered that CRBN is required for the anti-myeloma activity of IMiDs19,50 but IMiDs cannot improve the overall survival of multiple myeloma patients with p53 deficiency51, indicating the possible molecular linkage between CRBN and p53. Here, TP53 is linked to AL amyloidosis.